HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FSC/ETI repeal

This article was originally published in The Rose Sheet

Executive Summary

Conference report approved by U.S. House and Senate negotiators Oct. 6 would end retaliatory sanctions against the U.S. by Europe, including those on select cosmetic and fragrance ingredients. Report calls for repeal of the U.S. Foreign Sales Corporation/Extraterritorial Income Exclusion Subsidy, which allowed a portion of U.S. companies' income generated outside the U.S. to be exempt from taxes, and replace it with more than $8 bil. of transition relief over three years, House Committee on Ways and Means says. Presented by committee Chairman Bill Thomas (R-Calif.), the report still needs approval from full House and Senate. World Trade Organization gave the European Union the green light to impose tariffs on certain U.S. products, and in March, the EU announced it would impose a 5% customs duty on them (1"The Rose Sheet" March 8, 2004, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel